Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
---|---|---|---|---|---|
10232-2 | Dactolisib | BEZ235; NVP-BEZ235 | LSM-4255 | 11977753 | |
10133-2 | Afatinib | BIBW-2992 | LSM-43226 | 57519523 | |
10504-1 | Chk2 inhibitor II | BML-277 | 9969021 | ||
10258-1 | Ibandronate | Boniva | LSM-4279 | 44828485 | |
10245-1 | Cisplatin | CDDP; cis-Diaminodichloroplatinum; Cisplatinum; Lederplatin; Briplatin; Cismaplat | LSM-4268 | ||
10503-1 | Celecoxib | Celebrex; Celebra; Celecox; Onsenal; Solexa; SC-58635; YM-177 | 2662 | ||
10230-2 | Lestaurtinib | CEP-701 | LSM-1231 | 126565 | |
10048-7 | PD184352 | CI-1040 | LSM-1048 | 6918454 | |
10048-6 | PD184352 | CI-1040 | LSM-1048 | 6918454 | |
10346-1 | Valproic acid | Depakine | LSM-4620 | 3549980 | |
10249-1 | Epirubicin | Ellence | LSM-2078 | 41867 | |
10269-1 | Oxaliplatin | Eloxatin | LSM-44941 | 5310940 | |
10515-1 | QNZ | EVP4593 | 509554 | ||
10238-1 | 5-FU | Fluorouracil | LSM-4261 | 3385 | |
10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 | 11493598 | |
10252-1 | Gemcitabine | Gemzar | LSM-5333 | 60750 | |
10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 | 5291 | |
10142-2 | Trametinib | GSK-1120212; GSK1120212; GSK1120212B; JTP-74057 | LSM-1143 | 11707110 | |
10146-2 | Omipalisib | GSK2126458; GSK2126458A | LSM-1147 | 25167777 | |
10013-3 | GSK461364 | GSK461364A | LSM-1013 | 15983966 | |
10051-3 | Lapatinib | GW-572016; Tykerb | LSM-1051 | 208908 | |
10014-3 | GW843682X | GW843682 | LSM-1014 | 9826308 | |
10278-1 | Topotecan | Hycamtin | LSM-5662 | 60700 | |
10509-1 | GM6001 | Ilomastat; Galardin; GM-6001 | 132519 | ||
10246-1 | CPT-11 | Irinotecan | LSM-2167 | 60838 |